Bicyclic heterocycles as HIV integrase inhibitors

Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...

Reexamination Certificate

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

C514S259200, C514S222200, C544S003000, C544S278000, C540S552000

Reexamination Certificate

active

11138726

ABSTRACT:
The invention encompasses a series cyclic bicyclic heterocyclic compounds of Formula I which are inhibitors of HIV integrase and prevent viral integration into human DNA. This action makes the compounds useful for treating HIV infection and AIDS. The invention also encompasses pharmaceutical compositions and methods for treating those infected with HIV

REFERENCES:
patent: 2004/0006065 (2004-01-01), Glunz
patent: WO 2003/035076 (2003-05-01), None
patent: WO 2003/035077 (2003-05-01), None
patent: WO 2004/058756 (2004-07-01), None
patent: WO 2004/058757 (2004-07-01), None
patent: WO 2005/061490 (2005-07-01), None
patent: WO 2005/061501 (2005-07-01), None
patent: WO 2006/060731 (2006-06-01), None
patent: WO 2006/103399 (2006-10-01), None
U.S. Appl. No. 10/755,642, filed Jan. 12, 2004, Michael A. Walker, et al.

LandOfFree

Say what you really think

Search LandOfFree.com for the USA inventors and patents. Rate them and share your experience with other people.

Rating

Bicyclic heterocycles as HIV integrase inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Bicyclic heterocycles as HIV integrase inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Bicyclic heterocycles as HIV integrase inhibitors will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFUS-PAI-O-3772740

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.